BMS 986235
Alternative Names: BMS-986235; LAR-1219Latest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator Kyorin Pharmaceutical
- Developer Bristol-Myers Squibb; Kyorin Pharmaceutical
- Class Anti-inflammatories; Heart failure therapies; Small molecules
- Mechanism of Action Formyl peptide receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure; Inflammation
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Heart-failure(Prevention) in Japan
- 28 Apr 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (PO)
- 04 Apr 2022 BMS 986235 is still in phase I trials for Inflammation (In volunteers) in USA (PO) (NCT03335553)